Comparison of Clinical Features, Treatment and Outcomes of Lupus Nephritis Between Patients With Late- and Early-Onset Systemic Lupus Erythematosus: A Controlled Study
CONCLUSION: This matched controlled study of year at SLE diagnosis showed that late-onset SLE patients had lower prevalence of LN and LN flares. Although they received fewer immunosuppressive drugs, their renal manifestations and treatment outcomes were no different from those in early-onset patients.PMID:38550544 | PMC:PMC10970043 | DOI:10.14740/jocmr5097 (Source: Clin Med Res)
Source: Clin Med Res - March 29, 2024 Category: Research Authors: Jarukit Mongkolchaiarunya Antika Wongthanee Nuntana Kasitanon Worawit Louthrenoo Source Type: research
Systemic lupus erythematosus associated with erythema multiforme: A rare case report of Rowell's syndrome
Clin Case Rep. 2024 Mar 26;12(4):e8677. doi: 10.1002/ccr3.8677. eCollection 2024 Apr.ABSTRACTKEY CLINICAL MESSAGE: Although it is very uncommon, SLE may initially present with recurrent episodes of EM-like rash. Despite the various possibilities underlying their association, prompt identification, and treatment of SLE in patients presenting with EM is important to prevent death or serious organ damage.ABSTRACT: Rowell's syndrome (RS) is an uncommon presentation of systemic lupus erythematosus (SLE) with erythema multiforme (EM)-like lesions associated with specific serological changes, including positive rheumatoid factor ...
Source: Herpes - March 29, 2024 Category: Infectious Diseases Authors: Madhur Bhattarai Niraj Kumar Sharma Shreeram Paudel Sujata Bhandari Amrit Bhusal Kiran Dhonju Sandip Kuikel Shivendra Kumar Jha Egesh Aryal Deepak Subedi Source Type: research
Comparison of Clinical Features, Treatment and Outcomes of Lupus Nephritis Between Patients With Late- and Early-Onset Systemic Lupus Erythematosus: A Controlled Study
CONCLUSION: This matched controlled study of year at SLE diagnosis showed that late-onset SLE patients had lower prevalence of LN and LN flares. Although they received fewer immunosuppressive drugs, their renal manifestations and treatment outcomes were no different from those in early-onset patients.PMID:38550544 | PMC:PMC10970043 | DOI:10.14740/jocmr5097 (Source: Clin Med Res)
Source: Clin Med Res - March 29, 2024 Category: Research Authors: Jarukit Mongkolchaiarunya Antika Wongthanee Nuntana Kasitanon Worawit Louthrenoo Source Type: research
Comparison of Clinical Features, Treatment and Outcomes of Lupus Nephritis Between Patients With Late- and Early-Onset Systemic Lupus Erythematosus: A Controlled Study
CONCLUSION: This matched controlled study of year at SLE diagnosis showed that late-onset SLE patients had lower prevalence of LN and LN flares. Although they received fewer immunosuppressive drugs, their renal manifestations and treatment outcomes were no different from those in early-onset patients.PMID:38550544 | PMC:PMC10970043 | DOI:10.14740/jocmr5097 (Source: Clin Med Res)
Source: Clin Med Res - March 29, 2024 Category: Research Authors: Jarukit Mongkolchaiarunya Antika Wongthanee Nuntana Kasitanon Worawit Louthrenoo Source Type: research
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab
In conclusion, the 10 mg/kg IV dose was considered appropriate in all patients and there was no evidence to suggest a hig her response would be achieved by increasing the dose. (Source: Journal of Pharmacokinetics and Pharmacodynamics)
Source: Journal of Pharmacokinetics and Pharmacodynamics - March 29, 2024 Category: Drugs & Pharmacology Source Type: research
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
CONCLUSIONS: Beliefs about medications were a major determinant of medication non-adherence. Patient education may help alleviate the negative impact of misinformation/unawareness on adherence.PMID:38545763 | DOI:10.1177/09612033241242692 (Source: Lupus)
Source: Lupus - March 28, 2024 Category: Rheumatology Authors: Sharzad Emamikia Alvaro Gomez Theodor Ådahl Gunilla von Perner Yvonne Enman Katerina Chatzidionysiou Elizabeth V Arkema Ioannis Parodis Source Type: research
Systemic lupus erythematosus: one year in review 2024
Clin Exp Rheumatol. 2024 Mar;42(3):583-592. doi: 10.55563/clinexprheumatol/mnvmvo. Epub 2024 Mar 27.ABSTRACTSystemic lupus erythematosus (SLE) is classically regarded as the landmark of systemic autoimmune diseases, characterised by protean, multi-systemic manifestations and a highly variable clinical course.Over the last years, both clinical and translational clinical research efforts led to significant steps forward in management and treatment of SLE. However, numerous aspects of SLE, from pathogenesis to treatment, still remain challenging, and several unmet needs persist for both patients and physicians. Following the ...
Source: Clinical and Experimental Rheumatology - March 28, 2024 Category: Rheumatology Authors: Davide Schilir ò Ettore Silvagni Benedetta Cirib è Federico Fattorini Vincenzo Maccarrone Elena Elefante Viola Signorini Dina Zucchi Chiara Cardelli Alessandra Bortoluzzi Chiara Tani Source Type: research
Revolutionizing Treatment Strategies for Autoimmune and Inflammatory Disorders: The Impact of Dipeptidyl-Peptidase 4 Inhibitors
J Inflamm Res. 2024 Mar 23;17:1897-1917. doi: 10.2147/JIR.S442106. eCollection 2024.ABSTRACTDPP4 (Dipeptidyl-peptidase 4) a versatile protease, emerges as a prominent player in soluble and membrane-bound forms. Its heightened expression has been intimately linked to the initiation and severity of diverse autoimmune diseases, spanning rheumatoid arthritis, systemic lupus erythematosus, systemic sclerosis (SSc), inflammatory bowel disease, autoimmune diabetes, and even SARS-CoV-2 infection. Operating as a co-stimulator of T cell activity, DPP4 propels T cell proliferation by binding adenosine deaminase (ADA), thereby augment...
Source: Cell Research - March 28, 2024 Category: Cytology Authors: Kashif Rahim Muhammad Shan Ihtisham Ul Haq Muhammad Naveed Nawaz Sajida Maryam Mansour S Alturki Abdulaziz H Al Khzem Kamel Metwally Simona Cavalu Saleh F Alqifari Galal Yahya Source Type: research
Assessment of Arterial Stiffness and Biochemical Markers in Systemic Lupus Erythematosus in the Diagnosis of Subclinical Atherosclerosis
J Pers Med. 2024 Mar 8;14(3):289. doi: 10.3390/jpm14030289.ABSTRACTPatients with systemic lupus erythematosus (SLE) are 2-10 times more likely to develop cardiovascular disease (CVD) than the general population. The assessment of the risk of developing CVD is an important direction for further clinical management. The study was conducted retrospectively and included patients with SLE. The aim of the study was to assess the measurements of pulse wave velocity (PWV), carotid intima-media thickness (CIMT), ankle-brachial index (ABI) and biochemical parameters. Subclinical atherosclerosis was also assessed. The study included ...
Source: Atherosclerosis - March 28, 2024 Category: Cardiology Authors: Dominika Blachut Brygida Przywara-Chowaniec Michalina Mazurkiewicz Andrzej Tomasik Source Type: research
Fully human anti-CD19 CAR T cells derived from systemic lupus erythematosus patients exhibit cytotoxicity with reduced inflammatory cytokine production
CONCLUSION: Hu19-CD828Z CAR T cells generated from SLE patient lymphocytes demonstrate CAR-mediated and CD19-dependent activity against autologous primary B cells with reduced inflammatory cytokine production supporting KYV-101 as a novel potential therapy for the depletion of pathogenic B cells in SLE patients.PMID:38548226 | DOI:10.1016/j.jtct.2024.03.023 (Source: Cancer Control)
Source: Cancer Control - March 28, 2024 Category: Cancer & Oncology Authors: Janin Dingfelder Michael Aigner Jule Taubmann Ioanna Minopoulou Soo Park Charles D Kaplan Joseph K Cheng Tom Van Blarcom Georg Schett Andreas Mackensen Gloria Lutzny-Geier Source Type: research
Factors associated with non-adherence to medications in systemic lupus erythematosus: Results from a Swedish survey
CONCLUSIONS: Beliefs about medications were a major determinant of medication non-adherence. Patient education may help alleviate the negative impact of misinformation/unawareness on adherence.PMID:38545763 | DOI:10.1177/09612033241242692 (Source: Lupus)
Source: Lupus - March 28, 2024 Category: Rheumatology Authors: Sharzad Emamikia Alvaro Gomez Theodor Ådahl Gunilla von Perner Yvonne Enman Katerina Chatzidionysiou Elizabeth V Arkema Ioannis Parodis Source Type: research
Systemic Lupus Erythematosus-related Lung Disease
Semin Respir Crit Care Med. 2024 Mar 28. doi: 10.1055/s-0044-1782653. Online ahead of print.ABSTRACTSystemic Lupus Erythematosus (SLE) is a multifaceted, multisystem autoimmune disorder with diverse clinical expressions. While prevalence reports vary widely, pulmonary involvement accounts for significant morbidity and mortality in SLE. This comprehensive review explores the spectrum of pulmonary disease in SLE, including upper airway manifestations (e.g., laryngeal affection), lower airway conditions (e.g., bronchitis, bronchiolitis, bronchiectasis), parenchymal diseases (e.g., interstitial lung disease, acute lupus pneumo...
Source: Respiratory Care - March 28, 2024 Category: Respiratory Medicine Authors: Elisabeth Bendstrup Evelyn Lynn Anne Troldborg Source Type: research
Systemic lupus erythematosus: one year in review 2024
Clin Exp Rheumatol. 2024 Mar;42(3):583-592. doi: 10.55563/clinexprheumatol/mnvmvo. Epub 2024 Mar 27.ABSTRACTSystemic lupus erythematosus (SLE) is classically regarded as the landmark of systemic autoimmune diseases, characterised by protean, multi-systemic manifestations and a highly variable clinical course.Over the last years, both clinical and translational clinical research efforts led to significant steps forward in management and treatment of SLE. However, numerous aspects of SLE, from pathogenesis to treatment, still remain challenging, and several unmet needs persist for both patients and physicians. Following the ...
Source: Clinical and Experimental Rheumatology - March 28, 2024 Category: Rheumatology Authors: Davide Schilir ò Ettore Silvagni Benedetta Cirib è Federico Fattorini Vincenzo Maccarrone Elena Elefante Viola Signorini Dina Zucchi Chiara Cardelli Alessandra Bortoluzzi Chiara Tani Source Type: research
Assessment of Arterial Stiffness and Biochemical Markers in Systemic Lupus Erythematosus in the Diagnosis of Subclinical Atherosclerosis
J Pers Med. 2024 Mar 8;14(3):289. doi: 10.3390/jpm14030289.ABSTRACTPatients with systemic lupus erythematosus (SLE) are 2-10 times more likely to develop cardiovascular disease (CVD) than the general population. The assessment of the risk of developing CVD is an important direction for further clinical management. The study was conducted retrospectively and included patients with SLE. The aim of the study was to assess the measurements of pulse wave velocity (PWV), carotid intima-media thickness (CIMT), ankle-brachial index (ABI) and biochemical parameters. Subclinical atherosclerosis was also assessed. The study included ...
Source: Atherosclerosis - March 28, 2024 Category: Cardiology Authors: Dominika Blachut Brygida Przywara-Chowaniec Michalina Mazurkiewicz Andrzej Tomasik Source Type: research
